contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


aiforia-technologies-potential-tempts-get-back-board

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Head of Nordic ER Development, Analyst

Antti Luiro

Analyst

Frans-Mikael Rostedt

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Answering myself: The volume at Fimlab was approx. 1,600 slides in September 2025 and 3,500 in October, and the volume is growing. Price per slide taken from the comprehensive report  And with a good margin  Fimlab is, however, on the smaller end of the won tenders, so you would think it will gradually start showing on the bottom line once the scanners are installed

Imaging in this context refers to radiology, so the ambiguity you mentioned does not exist. Aiforia’s solutions are for clinical pathology and, as far as I know, they haven’t expressed interest in moving into competition for the analysis of radiology images.

That pathology field covers a lot of ground, and I suppose it’s about interpreting all kinds of samples digitally using AI, whether we’re talking about cancer, Alzheimer’s, etc., and I guess it relates to imaging depending on how one interprets it.

Of course, it’s worth remembering here that Aiforia’s solution is for pathology and not for imaging.

I’ve been checking the Siemens Healthineers website to see if there are any mentions. It seems like there are big medical events happening right now, with more to come. AI and imaging are being trumpeted everywhere. I have strong faith that some of this will benefit Aiforia too, but this really tests one’s staying power.

Without taking a position on the analysis itself, Nuways has a “buy” recommendation for almost every client, “under review” for a few, and a few unfortunate ones have been assigned a “hold”. In Germany, these views are consistently very positive.                    nuways-ag.com              Companies    Our research is free for everyone. Always. Discover exciting investment cases for your portfolio.                             From what I’ve seen of German companies, local research houses seem to operate on an “automatic-buy, target price 2x current price” model.

Pre-results update.  Despite the share price, target €3.80 & Buy Summary:  We remain upbeat on Aiforia’s Foundation Engine and its clinical and commercial scalability. Aiforia’s clinical footprint now covers breast, prostate, and lung cancers, strengthened by its new gastric cancer model. Supply–demand dynamics are supportive as hospitals face rising pressure to digitise pathology and adopt AI. In Lombardia, ~400 pathologists in 2025 are expected to fall by ~100 (due to retirements) by 2027 with only nine replacements, underscoring urgent automation needs. FY26 should bring additional tenders, including HUS, Finland’s largest hospital group (potentially in Q2). We reiterate our BUY rating with a € 3.80 PT based on our DCF model.                    Nuways AG              Aiforia Technologies Oyj

Aiforia Technologies

We still see clear potential for Aiforia to grow into one of the long-term winners in its market, although weak growth predictability and elevated financing risks argue for caution in pricing the potential. The expansion of the use of the company's software in its customer base seems to be taking time and we cut our growth forecasts slightly. However, we believe that the decline in the share price (-24%) since our last report compensated sufficiently for the cuts, and at the current price we see the company's value creation potential outweighing the risks.

<p>We still see clear potential for Aiforia to grow into one of the long-term winners in its market, although weak growth predictability and elevated financing risks argue for caution in pricing the potential. The expansion of the use of the company's software in its customer base seems to be taking time and we cut our growth forecasts slightly. However, we believe that the decline in the share price (-24%) since our last report compensated sufficiently for the cuts, and at the current price we see the company's value creation potential outweighing the risks.</p> 

	2022	23e	24e
Revenue	1.9	2.7	5.1
growth-%	91.8 %	46.5 %	86.9 %
EBIT (adj.)	-10.2	-12.1	-12.0
EBIT-% (adj.)	-546.2 %	-441.0 %	-235.3 %
EPS (adj.)	-0.41	-0.47	-0.46
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Aiforia Technologies: Potential tempts to get back on board

Key Estimate Figures2023-12-07

Forum discussions